Clinical trials: Cholangiocarcinomas
Cholangio Carcinoma
Treatment for Bile Duct Cancer in the Liver
The current standard treatment of inoperable intrahepatic cholangiocarcinoma (bile duct cancer in the liver) is chemotherapy, which is of limited efficacy.
- Trial name
- NCT02167711
- Testing
- SIRT Yttrium-90
- Where
- Hong Kong
- Volunteers
- 24 people
- Sponsor
- Chinese University of Hong Kong
Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8
Preoperative Nab-paclitaxel, Cisplatin, and Gemcitabine Chemotherapy With or Without Infigratinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, The OPTIC Trial
This phase II trial assesses the feasibility (including both safety and tolerability) of conducting Next Generation Sequencing and administering targeted therapy (infigratinib) in the preoperative setting for patients with…
- Conditions
- Resectable Intrahepatic Cholangiocarcinoma, Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8, Stage I Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC v8
- Trial name
- NCT05514912
- Testing
- Cisplatin, Gemcitabine Hydrochloride, Infigratinib Phosphate
- Sponsor
- Emory University
Cholangiocarcinoma
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered…
- Trial name
- FIRST-308 (NCT05948475)
- Testing
- Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
- Where
- 87 sites in United States, Austria and 11 more
- Volunteers
- 200 people
- Sponsor
- TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors
Biliary tract cancer (BTC) accounts for 4% of the malignant tumors of the digestive system, and the incidence has increased significantly in recent years.
- Trial name
- NCT04866836
- Testing
- Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent
En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to Improve the Overall Survival in Patients With Non-resectable Hilar Cholangiocarcinoma Beyond the Mayo Clinic Transplant Criteria
Surgery for hilar cholangiocarcinoma (phCCA) remains a significant challenge. The minority of patients who are eligible for resection are exposed to high procedure-related morbidity and mortality, and despite apparent R0…
- Conditions
- Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Recurrent, Liver Transplantation
- Trial name
- SURE-LT (NCT06850753)
- Testing
- Liver transplantation after en bloc resection of the liver and pancreas
- Where
- Norway
- Volunteers
- 15 people
- Sponsor
- Oslo University Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pain
- Trial name
- NCT00073905
- Testing
- capecitabine plus gemcitabine
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Swiss Cancer Institute
Extrahepatic Cholangiocarcinoma, Bile Duct Cancer
Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma
A median survival period of 3 to 6 months is the prognosis for patients with advanced, unresectable EHCC. For patients with locally advanced, unresectable EHCC, effective management of tumor growth is the only option to increase…
- Trial name
- NCT05519319
- Testing
- RFA, PDT, RFA combined with PDT
- Where
- China
- Volunteers
- 70 people
- Sponsor
- First People's Hospital of Hangzhou
Cholangiocarcinoma, Liver Fluke-Related Cholangiocarcinoma
Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand
Liver cancer, specifically cholangiocarcinoma (CCA), is very common in different areas in Thailand. Many factors make this cancer more common, such as liver fluke infection, older age, eating raw fish, family history of cancer…
- Conditions
- Cholangiocarcinoma, Liver Fluke-Related Cholangiocarcinoma, Opisthorchiasis
- Trial name
- eCHEC (NCT05321992)
- Testing
- eCHEC program
- Where
- Thailand
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- McMaster University
Biliary Tract Cancer, Gallbladder Cancer
Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers
The purpose of this study is to determine whether fit patients (with ECOG performance score of 0-1) with advanced biliary tract cancer (ABC) benefit from chemotherapy in the second-line setting (after prior therapy with cisplatin…
- Conditions
- Biliary Tract Cancer, Gallbladder Cancer, Cholangiocarcinoma, Ampullary Cancer
- Trial name
- ABC06 (NCT01926236)
- Testing
- Active Symptom Control, L-folinic acid, 5 FU
- Where
- 17 sites in United Kingdom
- Volunteers
- 162 people
- Sponsor
- The Christie NHS Foundation Trust
Resectable Intrahepatic Cholangiocarcinoma
Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial
This phase II trial tests the safety and effectiveness of preoperative immunotherapy with durvalumab and chemotherapy with cisplatin and gemcitabine with or without futibatinib targeted therapy in treating patients with…
- Trial name
- NCT07639528
- Testing
- Biospecimen Collection, Cisplatin, Computed Tomography
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Northwestern University
Intrahepatic Cholangiocarcinoma
Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma
The objective of this study is to evaluate the efficacy and safety of cryoablation combined with anti-pd-1 antibody in patients with advanced hepatocellular carcinoma after progression on first line systemic therapy.
- Trial name
- NCT04299581
- Testing
- Camrelizumab, US/CT-guided Percutaneous Cryoablation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fudan University
Cholangiocarcinoma, Pancreas Cancer
RFA for Malignant Biliary Obstruction
Pancreatic cancer and cholangiocarcinoma are the most common causes of malignant biliary obstruction. They are diseases of increasing incidence and unfavorable prognosis.
- Trial name
- NCT03166436
- Testing
- Radiofrequency ablation, Biliary stenting
- Where
- Czechia
- Volunteers
- 140 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Biliary Tract Cancer
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer
NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer.
- Trial name
- NCT04163900
- Testing
- NUC-1031, Gemcitabine, Cisplatin
- Where
- 125 sites in United States, Australia and 13 more
- Volunteers
- 773 people
- Sponsor
- NuCana plc
Hepatocellular Carcinoma, Metastasis
Radiofrequency Ablation Using Octopus Electrodes for Treatment of Focal Liver Malignancies
The purpose of this study is to evaluate the clinical feasibility and short-term outcome of switching monopolar RFA using a separable cluster electrode in patients with primary and secondary liver malignancies.
- Conditions
- Hepatocellular Carcinoma, Metastasis, Cholangiocarcinoma
- Trial name
- NCT02683538
- Testing
- Separable cluster electrode (Octopus®)
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Seoul National University Hospital
Cholangiocarcinoma
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy
This is a single arm, multicentre, Phase 2 study to assess efficacy and safety of ASLAN001 in patients with advanced or metastatic cholangiocarcinoma who progressed on at least 1 line of systemic therapy.
- Trial name
- NCT02609958
- Testing
- Varlitinib
- Where
- 3 sites in Singapore, South Korea and 1 more
- Volunteers
- 32 people
- Sponsor
- ASLAN Pharmaceuticals
Biliary Tract Carcinoma, Cholangiocarcinoma
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
This is a phase 2 study of gemcitabine, cisplatin, zimberelimab (AB122) and quemliclustat (AB680) in subjects with untreated advanced biliary tract cancers (BTC).
- Conditions
- Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer
- Trial name
- NCT06048133
- Testing
- Gemcitabine, Cisplatin, Zimberelimab
- Where
- 4 sites in United States
- Volunteers
- 33 people
- Sponsor
- Nataliya Uboha
Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma
NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma
This phase I trial tests the safety, best dose, and effectiveness of NXP800 in treating patients with cholangiocarcinoma that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Stage III Hilar Cholangiocarcinoma AJCC v8
- Trial name
- NCT06420349
- Testing
- Biospecimen Collection, Computed Tomography, Heat Shock Factor 1 Pathway Inhibitor NXP800
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Mayo Clinic
Uterine Cervical Neoplasms, Endometrial Neoplasms
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of pembrolizumab/vibostolimab co-formulation (MK-7684A) with or without other anticancer therapies in participants with selected…
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Squamous Cell Carcinoma of Head and Neck, Gallbladder Neoplasms
- Trial name
- NCT05007106
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Pembrolizumab, Lenvatinib
- Where
- 73 sites in United States, Canada and 13 more
- Volunteers
- 611 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Cancer, Cholangiocarcinoma
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
PLATON (Platform for Analyzing Targetable Mutations) is a prospective, multicentre, observational cohort study with biobanking. In a first approach PLATON's pilot-study assesses genomic profiling in gastrointestinal cancer…
- Conditions
- Hepatocellular Cancer, Cholangiocarcinoma, Gallbladder Cancer, Pancreatic Cancer
- Trial name
- PLATON (NCT04484636)
- Testing
- FoundationOne®CDx and FoundationOne®Liquid
- Where
- 46 sites in Germany
- Volunteers
- 400 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Pancreatic Disease, Pancreatic Cancer
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.
- Conditions
- Pancreatic Disease, Pancreatic Cancer, Pancreatic Cyst, Gastrointestinal Tumor
- Trial name
- NCT06340620
- Testing
- Endoscopic ultrasound examination
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- Orlando Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.